General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology. General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery. General Proximity, a San Francisco-based biotechnology company developing proximity-induced medicines, has signed a strategic multi-target collaboration with Daiichi Sankyo Co., Ltd. to co-develop cancer treatments using its proprietary OmniTAC discovery platform. The partnership, routed through the Daiichi Sankyo Research Institute in Boston, will focus on identifying first-in-class therapeutic candidates capable of modulating proteins traditionally viewed as "undruggable" in oncology.

General Proximity, a biotech platform company, has emerged from stealth with $16M in funding. The oversubscribed seed round was led by Aydin Senkut of Felicis, with participation from Y Combinator, age1, Modi Ventures, Wilson Sonsini, and angel investors like Jeff Dean and Ben Mann. The funds will accelerate the development of treatments targeting undruggable proteins related to cancer, cardiometabolic disease, neurodegeneration, and longevity.